Lung adenocarcinoma ROS1 gene mutation targeted therapy is effective. Lung adenocarcinoma ROS1 gene is one of the driving genes of lung cancer, and patients with mutation have already been treated with targeted drugs accordingly. Commonly used drugs include crizotinib, ceritinib, and loratinib, etc., which can target ROS1 more precisely to fight against the cancer cells, leading to the death of the cancer cells, and obtaining the best therapeutic effect. Take crizotinib as an example, the drug has three different targets, namely ROS1, ALK and MET, which can target the mutated ROS1 gene to inhibit the growth of tumor and cancer cells, stabilize the condition and prolong the survival cycle of patients, and the overall therapeutic effect is still relatively clear. However, after a long time of drug use, patients may still develop drug resistance, resulting in new progress of the disease, and need to look for other drugs or programs for treatment; in addition, patients may also develop cardiac, hepatic and renal toxicity during the use of the drug, and need to be actively dealt with.